论文部分内容阅读
目的 评价尿细胞角蛋白19片段(CK19,又称CYFRA2 1 1)在膀胱移行细胞癌(BTCC)术后监测中的作用。方法 对67例保留膀胱的BTCC术后患者定期行膀胱镜检查发现2 1例复发,采用电化学发光免疫分析(ECLIA)技术测定复发组(2 1例)、未复发组(4 6例)和正常对照组(2 4例)的尿CKl9含量。结果 复发组尿CKl9的平均值为(19.60±18.5 7) μg/L ,明显高于未复发组(2 .3 3±1.64 ) μg/L和正常对照组(1.82±0 .83 ) μg/L。复发组与未复发组及正常对照组比较,差异有统计学意义(P <0 .0 1)。尿CKl9对BTCC复发的敏感性为90 .5 % ,特异性为76.0 %。结论 尿CKl9是监测BTCC术后复发较为敏感、特异而且快速无创的指标
Objective To evaluate the role of urine cytokeratin 19 fragment (CK19, also known as CYFRA211) in postoperative surveillance of bladder transitional cell carcinoma (BTCC). Methods A total of 67 patients who underwent cystoscopy after BTCC with bladder preservation were found to undergo recurrent cystoscopy. A total of 21 cases were found to have recurrence. Electrochemiluminescence immunoassay (ECLIA) technique was used to determine the recurrence group (21 cases) and the non-recurrent group (46 cases). Urine CKl9 content in normal control group (24 cases). Results The mean value of urinary CK19 in recurrent group was (19.60±18.5 7) μg/L, which was significantly higher than that in non-recurrence group (2.33±1.64) μg/L and normal control group (1.82±0.83) μg/L. . The difference between the relapse group and the non-recurrence group and the normal control group was statistically significant (P < 0.01). The sensitivity of urinary CKl9 to recurrence of BTCC was 90.5 % with a specificity of 76.0%. Conclusion Urinary CKl9 is a sensitive, specific and rapid noninvasive indicator for monitoring recurrence after BTCC